192 related articles for article (PubMed ID: 11699607)
21. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
22. Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
Pauwels K; Huys I; Casteels M; Simoens S
BMC Health Serv Res; 2014 Sep; 14():438. PubMed ID: 25257912
[TBL] [Abstract][Full Text] [Related]
23. Access and use of WHO essential medicines in Italy.
Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
[TBL] [Abstract][Full Text] [Related]
24. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
25. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
[TBL] [Abstract][Full Text] [Related]
26. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
27. Health indicators in the European regions: expanding regional comparisons to the new countries of the European Union - ISARE III.
Wilkinson JR; Berghmans L; Imbert F; Ledésert B; Ochoa A;
Public Health; 2009 Jul; 123(7):490-5. PubMed ID: 19615705
[TBL] [Abstract][Full Text] [Related]
28. Analysis of citizens' subjective perception of safe antibiotic use in European Union countries.
Zilinskas G; Tamasauskiene L; Tamasauskas D
J Infect Public Health; 2019; 12(2):229-235. PubMed ID: 30389369
[TBL] [Abstract][Full Text] [Related]
29. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
30. Affordability of medicines in the European Union.
Zaprutko T; Kopciuch D; Kus K; Merks P; Nowicka M; Augustyniak I; Nowakowska E
PLoS One; 2017; 12(2):e0172753. PubMed ID: 28241019
[TBL] [Abstract][Full Text] [Related]
31. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
[TBL] [Abstract][Full Text] [Related]
32. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?
Abraham J; Lewis G
Soc Sci Med; 1999 Jun; 48(11):1655-67. PubMed ID: 10400264
[TBL] [Abstract][Full Text] [Related]
33. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
Ferrario A; Arāja D; Bochenek T; Čatić T; Dankó D; Dimitrova M; Fürst J; Greičiūtė-Kuprijanov I; Hoxha I; Jakupi A; Laidmäe E; Löblová O; Mardare I; Markovic-Pekovic V; Meshkov D; Novakovic T; Petrova G; Pomorski M; Tomek D; Voncina L; Haycox A; Kanavos P; Vella Bonanno P; Godman B
Pharmacoeconomics; 2017 Dec; 35(12):1271-1285. PubMed ID: 28836222
[TBL] [Abstract][Full Text] [Related]
34. European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe.
Adriaenssens N; Coenen S; Kroes AC; Versporten A; Vankerckhoven V; Muller A; Blix HS; Goossens H;
J Antimicrob Chemother; 2011 Aug; 66(8):1897-905. PubMed ID: 21622674
[TBL] [Abstract][Full Text] [Related]
35. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
[TBL] [Abstract][Full Text] [Related]
36. Drug data coding and analysis in epidemiologic studies.
Pahor M; Chrischilles EA; Guralnik JM; Brown SL; Wallace RB; Carbonin P
Eur J Epidemiol; 1994 Aug; 10(4):405-11. PubMed ID: 7843344
[TBL] [Abstract][Full Text] [Related]
37. [EURO-Medicines: a European program for bringing into agreement public health policies on drugs].
Calamo-Specchia F; Bucci R; Folino-Gallo P
Ann Ig; 1998; 10(5-6):405-12. PubMed ID: 10052204
[No Abstract] [Full Text] [Related]
38. Essential and non-essential drugs marketed by the 20 largest European pharmaceutical companies in developing countries.
Hartog R
Soc Sci Med; 1993 Oct; 37(7):897-904. PubMed ID: 8211308
[TBL] [Abstract][Full Text] [Related]
39. Variation in antibiotic use in the European Union.
Cars O; Mölstad S; Melander A
Lancet; 2001 Jun; 357(9271):1851-3. PubMed ID: 11410197
[TBL] [Abstract][Full Text] [Related]
40. [The network of official medicines control laboratories].
Buchheit KH; Wanko R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
